...we didn't drop below $6 for the options call. A market down over 200 points and this held the $6 range. Maybe, we can start looking for a new trading pattern above $6.50.
According to the brief, cohort 3 was around the same dosage as 145. So cohort 4 is better with a more powerful drug. I'm not an expert but I would assume Grade 3 puts a halt to further testing? Not sure how this works.
...with how low the volume has been the couple days. I think with options expiring tomorrow that the shorts are going to take this down. Got to be ready for the pullback. Then again the conference is next week.....who knows. The low volume at ATHs does concern me though.
I agree. Errors in measuring the tumors and possibly an anomaly are the major sources contributing to the ending of the 145 trial. I think it has, like you said, taught the company a lot. (not to mention what they say to the press; they are much more quiet these days) I like how they modified 1456 and so far are getting more and a bigger bang out of it. If this guy, who was with Merck, can come in and help them through rough patch then even better.
From your write up, my take away is the evaluation centers did not identify the size of the tumors properly. With this addition to the team, do you think with his expertise that the size of the tumors could end up being worse or better? With your statement I tend to believe that because the centers were possibly wrong then 145 is still good. If this is true, then PROCEED might actually still be somewhat beneficial. If the centers were grossly in error then might the results be worse than originally figured? I'm trying to think and consider both ends of the spectrum in regards to it being positive or negative.
I believe we will see this stock trade close to $12 until after next week when options will expire. Lot of options for $11 and $12 respectively. Now if the merger info comes out that might bounce us out of this range.
Nay, it will go to 6.47 then back down to 6.13 then to 5's next week, right? LOL
Drove it back down today. Everyone made their money and now its time to watch it go back into the 5's and sit idle. Wish investors would ascribe some value to the pipeline. Trading between 7-8 would be nice for a change.
Those that haven't yet, go check out the posters on their website. The Cowen presentation shows them achieving 100% cures in a couple diseases. Hopefully waiting will result in a huge payoff!
If he really made the comment of going from Phase 1B to Phase III, that is rather HUGE in my opinion. 145 laid the track, 1456 is charging right along behind it. Let's get back int he 30's again. I liked that day!!!!
but short interest is growing. Several reports out on the Google side saying it has gone up. At the same time Institutional ownership has grown. Hoping that this surge in share price isn't all the shorts piling in to only drive it down. Nasdaq does say the average is 10 days to cover. This would put the average short's time to cover into March which is hopefully when the CC will be out. Shorts may be making a play to turn positive news into a negative share price or if there is negative news, take advantage of it.
Maybe my thinking is wrong, and I challenge anyone to call me on it. If the OS results have now been pushed to July, does this not add validity that maybe the patients haven't passed away yet and the OS is running longer than anticipated meaning something positive? I would think that the longer and OS runs the better it means for the drug. Just my two cents. I welcome dialogue.
I dunno man. I'm not sure the market will support an upturn in bio's. I'm feeling pretty discouraged actually. Down A LOT of money. Not seeing the normal upturn before earnings release is also a bit disheartening. Hope cohort 4 is a success.
The snow storm kept them home. :)
they didn't happen to say what type of institutions did they? I'm probably ignorant here so pardon it, but would it be financial institutions or other big pharmaceutical institutions? Thanks!